Ozempic Is The New Botox And Big Pharma Is Printing Billions Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion.
FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List FDA introduces a green list to block unsafe GLP-1 drug imports, while WHO updates its essential medicines list to include diabetes and cancer treatments.
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk.
Down 34%, Should You Buy the Dip on Viking Therapeutics? Viking aims to enter the billion-dollar weight loss drug market.
Where Will Eli Lilly Be in 3 Years? The weight-loss drug opportunity could approach $100 billion by the end of the decade.
The Problem With Weight Loss Stocks There are new ways to tackle weight loss, but the stocks leading the way are lagging.
After Copycat Boom, China's Drugmakers Target Global Generics Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns.
Is Novo Nordisk Stock a Buy Now? A 57% risk reduction for heart attacks and strokes sounds like an amazing result.
Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock NOVO-NORDISK (NVO) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy.
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.
This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today? Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop and commercialize treatments.
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs.
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.
UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears Patients in UK struggle to obtain Mounjaro drug due to high demand, sharp price increase. Shortages causing stress and health risks.
